Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ensartinib Capsules in Healthy Chinese Volunteers
NCT03536481Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ensartinib in lung cancer (4 cohorts), sponsored by Betta Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 120 hours and Area Under the Plasma Concentration versus Time Curve at 120 hours. Started Jun 2018; status: completed.
02
Drugs
ensartinib
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03536481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536481.